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Bloodstream infections (BSIs) cause considerable 
morbidity and mortality.[1,2] Estimates suggest that 
10 - 13% of community-onset BSIs are fatal,[3,4] while 
23% of nosocomial BSIs resulted in death in one study 
in the USA.[4] A paediatric cohort study in Kenya 
reported a case fatality rate of 24% for community-acquired and 53% 
for hospital-acquired bacteraemia.[5] A systematic review of admissions 
to hospital in various regions of Africa estimated that 13.5% of adults 
and 8.2% of children had community-acquired BSIs,[6] indicating these 
are a common cause of illness and account for a substantial proportion 
of all healthcare admissions. Rapid diagnosis, identification of the 
causative bacteria and appropriate treatment are essential in mitigating 
the morbidity and mortality associated with BSIs.
The epidemiology of bacterial infections differs in community 
and hospital settings. The predominant bacteria causing community-
acquired infections are Gram-positive organisms, while hospital-
acquired infections are more frequently caused by Gram-negative 
bacteria.[4] This distinction has relevance to empirical treatment of 
suspected bacterial infection.
In the past decade, an additional category of healthcare-associated 
infection has been recognised, to cover infections in patients who 
have had recent contact with the healthcare system.[7] Healthcare-
associated infections are typically similar to hospital-acquired 
infections in terms of pathogens and susceptibility patterns. We 
have therefore chosen to combine hospital-acquired and healthcare-
associated infections as healthcare-acquired infections.
Increasing antibiotic resistance complicates treatment of infections, 
in some cases seriously diminishing the options for effective therapy,[8] 
and is often associated with worse outcomes.[9] Laboratory-based 
surveillance data for BSIs in South Africa (SA) are available; however, 
these data do not distinguish between community- and hospital-
acquired infection.[10] Regular surveillance and reporting of BSIs and 
antibiotic susceptibility, including differentiation of community- and 
healthcare-acquired infections, can assist in managing infections 
appropriately and in adapting local antibiotic stewardship policies.[11,12]
Groote Schuur Hospital (GSH) is a large tertiary academic and 
teaching hospital in Cape Town, SA. In this hospital, blood cultures 
are generally collected when a patient has clinical features of sepsis, 
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typically before commencing or changing antibiotic therapy. However, 
there are no explicit guidelines or policies around indications for 
taking of blood cultures, and practices may vary from clinician to 
clinician.
This report describes the distribution of organisms isolated in blood 
cultures at GSH during a 1-year period. Additionally, we describe the 
distribution of antibiotic resistance among some groups of pathogens. 
We adapted routine laboratory practices to allow for classification 
of infections as healthcare or community acquired and applied this 
stratification to analysis of pathogens and antibiotic susceptibility 
results.
Guidelines to clinicians on antimicrobial therapy of bloodstream 
and other infections are provided by means of an annually updated and 
freely available booklet. At the time of the study, prior authorisation 
of most second-line antibiotics was required.
Methods
Study design
This was a retrospective assessment of bacterial isolates collected at 
GSH over a 12-month period.
Data
All microbiology testing was conducted at the GSH National Health 
Laboratory Service microbiology laboratory, which uses the BACTEC 9240 
automated blood culture system (Becton Dickinson, USA). Identification 
and susceptibility testing was carried out using various standard methods 
employed in the laboratory. In the majority of cases standard biochemical 
tests and disc diffusion and gradient diffusion susceptibility tests were used 
for Gram-positive organisms, whereas a method of direct inoculation of 
the ID-GNB and the AST-N064 cards of the Vitek 2 system was used for 
Gram-negative organisms.[13] However, alternative methods were used if 
needed.
Susceptibility results were interpreted according to the Clinical 
Laboratory Standards Institute (CLSI) criteria for the relevant year.[14,15] 
While the appropriate breakpoints for cephalosporins were utilised, 
the laboratory at this time, in line with the contemporary national 
practice, continued to accept the suggestion of the Vitek Advanced 
Expert System to report extended-spectrum β-lactamase (ESBL)-
producing Enterobacteriaceae as resistant to all cephalosporins. 
In addition, ESBL production was not reported on the laboratory 
information system (LIS) owing to limitations in the design and setup 
of the interface linking the Vitek instrument and the LIS. Hence, 
for the purposes of this analysis, ESBL production was assumed if 
Enterobacteriaceae isolates were reported as resistant to cefepime. 
Staphylococcus aureus isolates with an inducible clindamycin 
resistance phenotype were reported as resistant to clindamycin.
Culture result data were extracted for every bloodstream isolate 
from GSH recorded in the laboratory database for the period 
1  October 2011 - 30 September 2012. To limit the data to single 
infection episodes, duplicates (defined as instances of an additional 
culture submitted from the same patient, isolating the same organism, 
within 14 days of a previous culture) were excluded.[5,16]
As part of regular practice, local microbiologists prospectively 
categorised each case of BSI after collecting relevant information from 
the attending clinician; this information was then recorded in a separate 
database, linkable by unique laboratory number.
Healthcare-acquired infections were defined as those in patients 
admitted to (any) hospital for at least 48 hours before developing signs and 
symptoms of infection, or who had been admitted to a healthcare facility 
within the 3 months preceding the date of blood culture. In addition, 
infections in patients living in a long-term care facility or receiving 
dialysis, chemotherapy or home-based intravenous therapy were also 
included as healthcare-acquired infections.[7] Community-acquired 
isolates were defined as those occurring before admission, or within the 
first 48 hours of admission in patients without recent hospitalisation in 
the past 3 months. Classification of isolates as contaminants was based 
on recognition of the organism as one commonly considered to be a 
contaminant (i.e. on the identity of the organism), provided this was 
supported by the treating clinician’s clinical assessment and decision 
not to provide therapy targeted to the isolate.[17] In the majority of cases 
in our hospital only a single blood culture is submitted per episode of 
sepsis. However, if multiple cultures were submitted, the number of 
positive blood culture bottles or sets was also used to determine whether 
an isolate was categorised as a contaminant or not. Isolates for which 
no clinical information was available, usually owing to early discharge 
of the patient, were also classified as contaminants. Additional study 
variables included the date on which the blood sample was taken, the 
age and gender of the patient, and the hospital ward where the patient 
was located.
Ethical approval for the study was granted through the University 
of Cape Town’s Faculty of Health Sciences Human Research Ethics 
Committee and the University of British Columbia’s Clinical Research 
Ethics Board.
Analysis
We used descriptive methods to assess the distribution of blood-
stream organisms and resistance patterns. Antibiotic susceptibility 
results were recorded in this database as susceptible, intermediate 
or resistant. Results are presented as the proportion of susceptible 
isolates out of the number of valid test results for that antibiotic 
and organism (or group of organisms). We further stratified the 
organism and susceptibility results by wards, grouped into categories 
of emergency, general medical, intensive care units (ICUs), maternity 
and surgery.
Fisher’s exact tests were used to compare the proportions, with 
p<0.05 considered statistically significant. Data preparation and 




There were 1 730 blood culture records from adults >13 years of 
age in the database; of these, 799 were considered pathogens and 
931 contaminants. One hundred and forty-three pathogens were 
removed as duplicates. After including multiple organisms isolated 
from individual blood cultures (87 additional pathogens), our dataset 
contained 740 pathogens, isolated from 653 episodes of BSI in 533 
patients. There were 981 organisms isolated from 931 blood cultures 
that were considered contaminants.
Demographics
Seventy-three per cent of the 653 episodes of illness (n=472) and 73% 
of the 740 organisms isolated (n=543) were healthcare acquired. The 
mean patient age was 49.6 years (standard deviation (SD) 19.8) for 
those with community-acquired infections, and 45.5 years (SD 16.8) 
for those with healthcare-acquired infections (Table 1).
Microbiology
Among community-acquired isolates, Gram-positive organisms were 
most common (54.3%, n=107), while there were 77 Enterobacteriaceae 
isolates (39.1%) (Table 2). Non-fermenting Gram-negative bacilli and 
fungi were rare. Streptococcus pneumoniae was the most frequently 
isolated organism (21.3%, n=42), followed by Escherichia coli (19.8%, 
n=39) and S. aureus (15.2%, n=30).
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Gram-negative bacilli constituted the largest 
group of healthcare-acquired isolates (68.0%, 
n=369) (Table 2). Gram-positive organisms 
and fungi accounted for 27.8% and 4.4%, 
respectively. Among the Gram-negative 
bacilli, Enterobacteriaceae predominated 
(39.4%, n=214), while non-fermenting Gram-
negative bacilli constituted 28.4% (n=154). 
The most commonly isolated healthcare-
acquired organisms were Acinetobacter 
baumanii complex (16.0%, n=87), Klebsiella 
spp. (15.8%, n=86), S. aureus (11.6%, n=63) 




gens demonstrated mini mal resistance to 
most first-line antibiotic agents used for 
treatment. All S. aureus isolates (n=30) 
were susceptible to cloxacillin, and 28 and 
29 were susceptible to erythromycin and 
clindamycin, respectively (Fig. 1). The 
majority of S. pneumoniae isolates (35/42, 
83%) were fully susceptible to penicillin 
(minimum inhibitory concentration (MIC) 
≤0.06 µg/mL) while the remainder (7/42, 
17%) had MICs in the range of 0.12 - 2 µg/
mL, meaning that they would be categorised 
as resistant in cases of meningitis, but 
susceptible for infections outside the central 
nervous system. All S. pneumoniae isolates 
were susceptible to ceftriaxone according to 
meningitis breakpoints (MIC ≤0.5 µg/mL).
The majority of Enterobacteriaceae 
were susceptible to gentamicin (95.6%), 
ceftriaxone (96.1%) and ciprofloxacin 
(92.2%) (Fig. 2). The proportion of ESBL-
producing Enterobacteriaceae was just 
under 5%, and 79.1% were susceptible to 
amoxicillin/clavulanate.
Healthcare-acquired isolates
Resistance was higher among healthcare-
acquired pathogens. Just over half of S. 
aureus isolates were susceptible to cloxacillin 
and to clindamycin (52.4% and 55.6%, 
respectively) (Fig. 3). No vancomycin 
resistance was detected in the 41 enterococcal 
isolates. Among the Enterobacteriaceae, 
only 41.4% were susceptible to amoxicillin/
clavulanate, 64.6% to gentamicin and 70% 
to ciprofloxacin (Fig. 3). ESBL production 
occurred in 39.6%. More than 99% were 
susceptible to the carbapenems, including 
ertapenem, meropenem and imipenem. 
Susceptibility to amikacin was 85.4%. 
Susceptibility to piperacillin/tazobactam was 
not reported owing to incomplete testing 
as a result of limitations of the Vitek 2 
Gram-negative susceptibility card in use at 
the time (Product Correction/Field Safety 
Notice Vitek® 2 Piperacillin/Tazobactam 
Memo, communication from bioMerieux, 
5 April 2011).
Pseudomonas aeruginosa showed 
relatively low susceptibility rates to most 
agents tested, ranging from 44.4% for 
imipenem and ciprofloxacin to 72.2% for 
ceftazidime (data not shown). Colistin was 
the only agent that retained high levels 
of susceptibility (91.7%). Susceptibility 
rates for piperacillin/tazobactam could not 
be reported for P. aeruginosa isolates for 
the same reason as above. A. baumanii 
complex also demonstrated low levels of 
susceptibility: only tobramycin and colistin 
retained susceptibility rates above 70% 
(72.1% and 96.6%, respectively) (data not 
shown).
Table 1. Demographics of patients with BSIs at GSH, 1 October 2011 - 30 September 2012
Adults (≥13 years) (N=653)
Community acquired Healthcare acquired
Total,* n (%) 181 (27.7) 472 (72.3)
Males, n (%) 75 (44.4) 270 (60.3)
Age (years), mean (SD) 49.6 (19.8) 45.5 (16.8)
*Total is number of BSI episodes; some patients had more than one episode, and if these were considered distinct, they were 
counted separately.
Table 2. Distribution of organisms causing BSIs among adults at GSH,  










Gram-negative bacilli    
Enterobacteriaceae 77 (39.1) 214 (39.4)
Enterobacter 5 (2.5) 38 (7.0)
E. coli 39 (19.8) 54 (9.9)
K. pneumoniae 14 (7.1) 86 (15.8)
Salmonella spp. 9 (4.6) 1 (0.2)
Other* 10 (5.1) 35 (6.4)
Non-fermentative Gram-negative bacilli 5 (2.5) 154 (28.4)
A. baumanii complex 1 (0.5) 87 (16.0)
P. aeruginosa 4 (2.0) 37 (6.8)
Other† - 30 (5.5)
Other Gram-negatives‡ 4 (2.0) -
Gram-positive
Staphylococci 35 (17.8) 99 (18.2)
S. aureus 30 (15.2) 63 (11.6)
Coagulase-negative staphylococci 5 (2.5) 36 (6.6)
Streptococci 61 (31.0) 11 (2.0)
β-haemolytic streptococci 13 (6.6) -
S. pneumoniae 42 (21.3) 4 (0.7)
Other α-haemolytic streptococci 6 (3.0) 7 (1.3)
Enterococci 5 (2.5) 41 (7.6)
Other 6 (3.0) -
Fungi 4 (2.0) 24 (4.4)
Candida spp. 1 (0.5) 24 (4.4)
Cryptococcus neoformans 3 (1.5) -
*Includes Citrobacter, Morganella, Pantoea, Proteus, Providencia, Raoultella and Serratia. 
†Includes Stenotrophomonas maltophilia.
‡Includes anaerobes and fastidious Gram-negative bacilli.
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Ward stratification
The ward distribution of healthcare-
acquired organisms is shown in Table 3. Half 
(n=271, 49.9%) of all healthcare-acquired 
isolates were associated with ICUs. Of 
these, nearly a quarter were identified as 
A. baumanii complex (n=65, 24.0%), while 
just over one-tenth were K. pneumoniae 
(n=33, 12%). In contrast, 28% of isolates 
were associated with general surgical wards 
(n=153, 28.2%), with equal numbers of 
E. coli and K. pneumoniae predominating 
(n=26, 17.0%). Fewer healthcare-associated 
isolates were associated with emergency 
(n=34, 6.3%) and general medical wards 
(n=76, 14.0%), but among these, the 
predominant organisms were S. aureus 
(emergency n=8, 23.5%; general medical 
n=18, 23.7%), K. pneumoniae (emergency 
n=8, 23.5%; general medical n=10, 13.2%) 
and E. coli (emergency n=7, 20.6%; general 
medical n=11, 14.5%) (Table 3). The number 
of healthcare-acquired isolates associated 
with the maternity wards was very small 
(n=9), so no further analysis of these isolates 
is presented.
The susceptibility profiles of selected 
pathogens isolated from different wards 
are shown in Figs 4 - 6. There were no 
statistically significant differences in the 
proportions susceptible to antibiotics in 
different wards, apart from E. coli isolates 
in the emergency ward (n=7), which were 
significantly more susceptible (100%) to 
ciprofloxacin than isolates from the ICUs 
(40%, n=10), and Acinetobacter isolates in 
the ICUs (n=65), which were significantly 
less susceptible to tobramycin (67.7%) and 
to amikacin (39%) than those associated 
with surgical wards (n=14, 100% and 78% 
susceptibility, respectively) (p<0.05 for all 
comparisons).
Discussion
Three-quarters of BSIs in adults at GSH 
are healthcare acquired. Although this 
may be partially expected at a tertiary 
hospital receiving many patients referred 
from other institutions, and therefore fewer 
community-acquired infections, this high 
proportion does illustrate the potential 
for reduction in numbers of BSIs through 
preventive measures, e.g. prompt removal of 
unnecessary intravenous lines and urinary 
catheters, and through improved hand 
hygiene.
The predominance of Gram-positive 
organisms among community-acquired 
infections and Gram-negative organisms 
among healthcare-acquired infections was 
confirmed in this study. Overall the most 
prevalent organisms responsible for com-
munity-acquired (S. pneumoniae, E. coli, S. 
aureus and K. pneumoniae) and healthcare-
acquired (Acinetobacter spp., Klebsiella spp., 
S. aureus, E. coli, enterococci, Enterobacter 
spp., P. aeruginosa, and coagulase-negative 
staphylococci) BSIs in our study were gener-
ally consistent with other recent studies.[18,19] 
Klebsiella spp., S. aureus and E. coli were the 
commonest causes of healthcare-acquired 
infections in all areas outside the ICUs, 
whereas Acinetobacter was common in the 
ICUs and rare in all other areas.
Community-acquired bloodstream patho -
gens in this hospital remain largely suscep-
tible to the first-line antibiotics, but anti-
biotic resistance is relatively common among 
healthcare-acquired bloodstream pathogens. 
Given that more than 50% of S. aureus 
isolates are resistant to cloxacillin, empiri-
cal vancomycin is appropriate for serious 
healthcare-acquired S. aureus infections. 
Likewise, with 40% of healthcare-acquired 



















Fig. 1. Antibiotic susceptibility of S. aureus isolated from BSIs among adults (≥13 years) at GSH, 














































































Fig. 2. Antibiotic susceptibility of Enterobacteriaceae isolated from BSIs among adults (≥13 years) at 
GSH, 1 October 2011 - 30 September 2012. 
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Enterobacteriacae being ESBL producers, 
the use of ertapenem for suspected Gram-
negative sepsis in this hospital seems justi-
fied. Amikacin is one possible alternative 
(85% susceptibility), but unfortunately it 
was not possible to investigate the propor-
tion of isolates susceptible to the previously 
used combination of piperacillin-tazobac-
tam and amikacin. In the ICUs, colistin or 
tobramycin may be needed for Acinetobacter 
infections. These conclusions are in line 
with contemporary hospital antibiotic rec-
ommendations.
Compared with a previous report that 
included data from GSH from 2010,[10] a 
lower proportion of healthcare-acquired S. 
aureus were susceptible to cloxacillin (52.4% 
v. 69%) and clindamycin (55.6% v. 71%) 
in the present study. The proportion of 
susceptible A. baumanii isolates was also 
lower in the present study with regard to 
ceftazidime (20.7% v. 49%), imipenem 
(18.4% v. 26%), meropenem (18.6% v. 
23%) and gentamicin (39.1% v. 47%). The 
likely reasons for these differences are the 
stratification of isolates into community- and 
healthcare-acquired infections, as well as the 
exclusion of contaminants and duplicates.[10]
Our results confirm the low susceptibility 
rates for P. aeruginosa and A. baumannii 
that have been reported in SA national 
surveillance data and in studies from other 
countries (although numbers of isolates 
may be low for confident comparisons) 
and reinforce the reliance on colistin as 
the sole agent that retains activity against 
most strains.[20] The ward-stratified results 


























Fig. 3. Antibiotic susceptibility of S. aureus causing healthcare-acquired BSIs among adults (≥13 years) 
at GSH, 1 October 2011 - 30 September 2012, according to ward groups.
Table 3. Distribution of organisms causing healthcare-acquired BSIs  among adults (≥13 years) at GSH, 1 October 2011 -  














Enterobacteriaceae 17 (7.9) 28 (13.1) 83 (38.8) 1 (0.5) 85 (39.7) 214 (39.4)
E. cloacae complex -15 3 (3.9) 16 (5.9) - 15 (9.8) 34 (6.3)
E. coli 7 (20.6) 11 (14.5) 10 (3.7) - 26 (17.0) 54 (9.9)
K. pneumoniae 8 (23.5) 10 (13.2) 33 (12.2) 1 (11.1) 26 (17.0) 78 (14.4)
Serratia marcescens - - 10 (3.7) - 2 (1.3) 12 (2.2)
Other 2 (5.9) 4 (5.3) 14 (5.2) - 16 (10.5) 36 (6.6)
Gram-negative non-fermenting bacilli 3 (8.8) 8 (10.5) 110 (40.6) 8 (88.9) 25 (16.3) 154 (28.4)
A. baumanii complex - 4 (5.3) 65 (24.0) 4 (44.4) 14 (9.2) 87 (16.0)
P. aeruginosa 3 (8.8) 2 (2.6) 20 (7.4) 1 (11.1) 11 (7.2) 37 (6.8)
 Stenotrophomonas maltophilia - 2 (2.6) 17 (6.3) 1 (11.1) - 20 (3.7)
Other - - 8 (3.0) 2 (22.2) - 10 (1.8)
Gram-positive 14 (41.2) 36 (47.4) 63 (23.2) - 38 (24.8) 151 (27.8)
Enterococcus faecalis 1 (2.9) 3 (3.9) 14 (5.2) - 3 (2.0) 21 (3.9)
E. faecium - 6 (7.9) 9 (3.3) - 3 (2.0) 18 (3.3)
S. aureus 8 (23.5) 18 (23.7) 20 (7.4) - 17 (11.1) 63 (11.6)
S. epidermidis 3 (8.8) 5 (6.6) 10 (3.7) - 6 (3.9) 24 (4.4)
Other 2 (5.9) 4 (5.3) 10 (3.7) - 9 (5.9) 25 (4.6)
Fungi - 4 (5.3) 15 (5.5) - 5 (3.3) 24 (4.4)
Candida albicans - 2 (2.6) 11 (4.1) - 3 (2.0) 16 (2.9)
Other - 2 (2.6) 4 (1.5) - 2 (1.3) 8 (1.5)
Total 34 (100.0) 76 (100.0) 271 (100.0) 9 (100.0) 153 (100.0) 543 (100.0)
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and their susceptibility patterns do not differ 
significantly by ward, apart from the greater 
proportion and more resistant Acinetobacter 
isolates associated with ICUs. This finding 
may be limited by the small numbers of 
isolates per ward.
Surveillance of antibiotic resistance, 
locally as well as regionally and globally, 
is important. Consistent application 
of standard definitions will assist in this 
ongoing endeavour. As has been pointed out 
previously,[10] laboratory-based surveillance 
depends on the culture submission practices 
of clinicians. Data should be maintained and 
extractable with an emphasis on facilitating 
regular analysis and reporting. Reporting 
should be based on standards that can be 
widely accepted and applied.
Study limitations
The chief limitation of this study was 
our inability to retrospectively assess the 
accuracy of the contaminant classification. 
These may be genuine contaminants, 
but could also include isolates for which 
clinical information was lacking or represent 
instances of error or omission by the 
reporting microbiologist. The majority 
of the group designated as contaminants 
were coagulase-negative staphyloccci or 
corynebacteria, which are recognised skin 
flora. However, some fungi and mycobacteria 
were not classified; these are likely to be 
mostly community acquired. Small numbers 
of Enterobacteriaceae (n=34) and S. aureus 
(n=24) were probably incorrectly excluded 
from the analysis of pathogens; however, 
the number of these relative to the numbers 
included was low (290 and 93 included, 
respectively). Improvements to the reporting 
system, such as inclusion of additional 
reporting items to differentiate unclassified 
isolates, as well as monthly review of data, 
could minimise these deficiencies.
Another important limitation concerns 
the reporting of all ESBL producers as 
resistant to all cephalosporins. Potentially, 
a proportion of these isolates would be 
susceptible to cephalosporins, particularly 
cefepime. However, evidence suggests that 
carriage of multiple ESBL genes is common 
in SA,[21] and at the time of writing this 
matter is still under discussion by national 
microbiology groups. As the study spanned 
2011 and 2012, the CLSI interpretive 
criteria that were applied differed over time. 
However, the changes were relatively few 
in number, and did not affect the major 
findings in relevant antibiotic susceptibilities 
in this study or alter the empirical treatment 
recommendations.
This report does not allow us to discuss 
trends in resistance patterns over time, 
as the analysis was conducted cross-
sectionally. Additionally, the data do not 




























Fig. 6. Antibiotic susceptibility of A. baumannii complex causing healthcare-acquired BSIs among 






























Fig. 4. Antibiotic susceptibility of E. coli causing healthcare-acquired BSIs among adults (≥13 years) at 






























Fig. 5. Antibiotic susceptibility of K. pneumoniae causing healthcare-acquired BSIs among adults (≥13 
years) at GSH, 1 October 2011 - 30 September 2012, according to ward groups.
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infection, either healthcare or community acquired. Changes in 
culture submission practices over time may have an impact on 
these reported susceptibility results. As with other studies of this 
nature, if clinicians are more likely to submit cultures for infections 
that are not responding to initial empirical treatment, the overall 
resistance rate will be inflated. We are not aware of any hospital-
based outbreaks occurring during the study period that would have 
biased our results.
Conclusion
The distinction between community- and healthcare-acquired 
acquisition of infection is relevant and important to empirical 
treatment options of BSIs. The findings presented here suggest 
that healthcare-acquired bloodstream pathogens carry significant 
resistance phenotypes. As hospital antibiotic use places substantial 
selection pressure on circulating organisms, efforts must continue to 
be directed towards improving the appropriateness of antibiotic use. 
This includes selection of an effective antimicrobial agent, as well as 
prescribing the optimal dose and duration, for all clinically important 
bacterial infections.
Community-acquired BSIs in this region retain considerable 
susceptibility to the antibiotics commonly used to treat them. 
Antibiotic stewardship efforts will be supported by the selection 
of relatively narrow-spectrum antibiotics for community-acquired 
infections, even in the tertiary setting. Resistance should be monitored 
closely so that treatment and antibiotic stewardship practice can 
continue to be informed by local susceptibility patterns.
Differentiation of community- and healthcare-acquired BSIs 
provides additional useful information, and could be readily 
incorporated into routine laboratory practice by any laboratory 
that conducts similar clinical liaison, although measures to ensure 
accuracy of classification should be included.
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DOCTORS CALL FOR LAWYERS TO GET OUT OF HOSPITALS
The South African Medical Association Trade Union (SAMA TU) would like to join the health minister Dr Aaron Motsoaledi in 
calling for “lawyers to get out of hospital and go back to court, and for doctors to get out of courts and go back to hospital”. The 
increasing frequency and value of medical malpractice claims threatens delivery of health services to the nation, especially the 
poor. We also agree that access to justice for those who have genuinely suff ered at the hands of the healthcare system should 
never be compromised. However, prevention is better than cure and as stakeholders in health we need to improve the access 
to and quality of our services.
We would like to declare our support and dedicated participation in the minister’s current medico-legal summit. We hope 
this summit will come up with tangible resolutions and an action plan that will put patients fi rst, protect the interests of the 
nation, and regulate the healthcare system in a just way. The impact of medico-legal cases has dire consequences for everyone; 
the limited resources are diverted from life-saving activities, while there is a risk of extinction of critical medical specialties 
such as gynaecologists, neurosurgery, anaesthesiology, neonatology and others. As SAMA TU we will embark on a nationwide 
programme to educate doctors on medico-legal issues, and put more emphasis on improving the quality and access to 
healthcare.
SAMA MED-e-MAIL, 10 March 2015
